Caladrius Biosciences Inc  

(Public, NASDAQ:CLBS)   Watch this stock  
Find more results for CLBS
3.50
-0.06 (-1.69%)
Dec 12 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 3.48 - 3.58
52 week 2.63 - 7.79
Open 3.57
Vol / Avg. 0.00/66,449.00
Mkt cap 33.15M
P/E     -
Div/yield     -
EPS -2.07
Shares 9.47M
Beta 1.60
Inst. own 19%
Nov 9, 2017
Q3 2017 Caladrius Biosciences Inc Earnings Call
Nov 9, 2017
Q3 2017 Caladrius Biosciences Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '17) 2016
Net profit margin - -94.40%
Operating margin - -88.81%
EBITD margin - -81.03%
Return on average assets -20.36% -60.17%
Return on average equity -25.52% -228.39%
Employees 209 -
CDP Score - -

Address

110 Allen Rd
BASKING RIDGE, NJ 07920-4500
United States - Map
+1-908-8420100 (Phone)
+1-845-8183588 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Caladrius Biosciences, Inc. is a cell therapy development company with product candidates in development based on multiple technology platforms and targeting autoimmune and cardiology indications. The Company's lead product candidate, CLBS03, is a T regulatory cell (Treg) clinical Phase II therapy targeting adolescents with recent-onset type 1 diabetes mellitus (T1DM) using the patient's own numerically and functionally enhanced Tregs. This therapy is based on a platform technology for immunomodulation. The Company is focused on commencing The Sanford Project: T-Rex Study, a Phase II prospective, randomized, placebo-controlled, double-blind clinical trial to evaluate its Treg product candidate, CLBS03, in adolescents with recent onset T1D. The Company plans to develop its product candidate, CLBS12, in Japan, which is an autologous therapy that derives its cells from peripheral blood through apheresis.

Officers and directors

David J. Mazzo Ph.D. Chief Executive Officer, Independent Director
Age: 59
Bio & Compensation  - Reuters
Joseph Talamo Chief Financial Officer, Senior Vice President
Age: 47
Bio & Compensation  - Reuters
Douglas W. Losordo M.D. Chief Medical Officer
Age: 58
Bio & Compensation  - Reuters
Gregory B. Brown M.D. Director
Age: 64
Bio & Compensation  - Reuters
Richard J. Berman J.D. Independent Director
Age: 73
Bio & Compensation  - Reuters
Drew Bernstein CPA., Independent Director
Age: 59
Bio & Compensation  - Reuters
Martyn D. Greenacre Independent Director
Age: 75
Bio & Compensation  - Reuters
Steven Mark Klosk Independent Director
Age: 60
Bio & Compensation  - Reuters